1. Home
  2. MYSE vs INTS Comparison

MYSE vs INTS Comparison

Compare MYSE & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Myseum Inc.

MYSE

Myseum Inc.

HOLD

Current Price

$2.47

Market Cap

11.2M

ML Signal

HOLD

Logo Intensity Therapeutics Inc.

INTS

Intensity Therapeutics Inc.

HOLD

Current Price

$4.10

Market Cap

10.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MYSE
INTS
Founded
2014
2012
Country
United States
United States
Employees
11
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.2M
10.8M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
MYSE
INTS
Price
$2.47
$4.10
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
$38.00
AVG Volume (30 Days)
261.8K
43.8K
Earning Date
05-13-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.31
$0.19
52 Week High
$5.77
$8.06

Technical Indicators

Market Signals
Indicator
MYSE
INTS
Relative Strength Index (RSI) 62.66 47.85
Support Level $1.61 $0.32
Resistance Level $2.80 $8.06
Average True Range (ATR) 0.26 0.24
MACD 0.09 0.08
Stochastic Oscillator 74.25 94.27

Price Performance

Historical Comparison
MYSE
INTS

About MYSE Myseum Inc.

Myseum.AI Inc is an integrate proprietary privacy-first artificial intelligence (AI) and social media technology company. The Company is developing privacy-first agentic localized AI agents to assist in managing personal media such as photos, videos and messages, while maintaining privacy.

About INTS Intensity Therapeutics Inc.

Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.

Share on Social Networks: